Oravax Medical
Company Details
Status: Private
Employees: 11-50
Location:
New York, New York, United States
Type:
sample
Technology:
sample
sample
sample
About: Oravax Medical is developing an oral COVID-19 vaccine.
The Oravax technology seamlessly integrates a novel approach to vaccines with a proprietary oral delivery platform. Oravax's COVID-19 vaccine candidate benefits from being a virus like particle (VLP) triple antigen vaccine that targets three structural proteins, which should make it a better candidate for protection across emerging mutations of the coronavirus. The oral delivery of the vaccine ought to allow for widescale inoculation and easier distribution of the vaccine without requiring an injection.
Oravax was established by Oramed Pharmaceuticals Inc., the largest shareholder in Oravax, along with Premas Biotech with a mission of bringing an oral COVID-19 vaccine to the market.
Unlock access to company contacts, hot leads, and drug pipelines.
Log in or create a free account now!
Oravax Medical | Active clinical trials on ClinicalTrials.gov
Active Clinical Trials Count | 0
No Active Trials Found On ClinicalTrials.gov.